{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T16:27:22Z","timestamp":1757780842988,"version":"3.41.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"18","license":[{"start":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T00:00:00Z","timestamp":1620345600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81970274"],"award-info":[{"award-number":["81970274"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007547","name":"Fourth Military Medical University","doi-asserted-by":"crossref","award":["81470479"],"award-info":[{"award-number":["81470479"]}],"id":[{"id":"10.13039\/501100007547","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Background: Atrial fibrillation (AF) is a type of arrhythmia that represents a severe health hazard. The current therapies for AF have achieved success in some conditions. However, because the mechanisms underlying the occurrence and development of this disease remain unclear, the current treatment for AF often does not achieve the desired outcomes. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), which exert robust effects on specific cardiovascular diseases, are widely used in the clinic. Several studies are focusing on the effect of ACEIs\/ARBs on the prevention and cure of AF. Some systematic reviews have obtained different and even opposite results. An overview is required to obtain a conclusion and provide strong evidence to guide clinical work.<\/jats:p>\n            <jats:p>Methods: We searched 5 databases, including MEDLINE, EMBASE, Cochrane Library, Web of Science, and CNKI (Chinese), and selected relevant reviews that passed the assessment we performed. Then, we synthesized the data for each result from the included reviews and obtained conclusions.<\/jats:p>\n            <jats:p>Results: ACEIs\/ARBs prevented new-onset AF and AF after heart failure. ACEIs\/ARBs performed well in the prevention of secondary AF, especially postoperative AF. However, for patients suffering from hypertension and myocardial infarction, ACEIs\/ARBs were not the right choices for preventing AF.<\/jats:p>\n            <jats:p>Conclusions: We suggest that physicians select ACEIs\/ARBs as an anti-AF therapy for patients with heart failure due to their additional benefits. Moreover, for patients who have suffered AF, ACEIs\/ARBs may be a routine drug for secondary prevention.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000025559","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T08:29:09Z","timestamp":1620289749000},"page":"e25559","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Inhibition of the renin-angiotensin-aldosterone system prevents and cures atrial fibrillation"],"prefix":"10.1097","volume":"100","author":[{"given":"Zhixiang","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Xijing Hospital, The Air Force Military Medical University, Xi\u2019an Shaanxi, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuhe","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fu","family":"Yi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Xijing Hospital, The Air Force Military Medical University, Xi\u2019an Shaanxi, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,5,7]]},"reference":[{"key":"R1-20250613","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jacc.2008.05.042","article-title":"Epidemiology, risk factors for stroke, and management of atrial fibrillation in China","volume":"52","author":"Hu","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R2-20250613","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1161\/01.CIR.0000145143.19711.78","article-title":"Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association","volume":"110","author":"Newburger","year":"2004","journal-title":"Circulation"},{"key":"R3-20250613","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/j.1540-8167.2010.01770.x","article-title":"The impact of new and emerging clinical data on treatment strategies for atrial fibrillation","volume":"21","author":"Prystowsky","year":"2010","journal-title":"J Cardiovasc Electrophysiol"},{"key":"R4-20250613","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2459\/JCM.0b013e328358554b","article-title":"Risk factors for atrial fibrillation recurrence: a literature review","volume":"15","author":"Vizzardi","year":"2014","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"R5-20250613","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ijcard.2018.03.049","article-title":"Transformation from persistent atrial fibrillation to paroxysmal type after initial ablation predicts success of repeated ablation","volume":"268","author":"Xing","year":"2018","journal-title":"Int J Cardiol"},{"key":"R6-20250613","first-page":"608","article-title":"Primary prevention of atrial fibrillation where are we in 2012?","volume":"5","author":"Imazio","year":"2012","journal-title":"J Atr Fibrillation"},{"key":"R7-20250613","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10741-019-09837-7","article-title":"Angiotensin II and angiotensin 1-7: which is their role in atrial fibrillation?","volume":"25","author":"Mascolo","year":"2020","journal-title":"Heart Fail Rev"},{"key":"R8-20250613","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"R9-20250613","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2522\/ptj.20070043","article-title":"Physical therapy interventions for patients with osteoarthritis of the knee: an overview of systematic reviews","volume":"88","author":"Jamtvedt","year":"2008","journal-title":"Phys Ther"},{"key":"R10-20250613","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2288-7-10","article-title":"Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews","volume":"7","author":"Shea","year":"2007","journal-title":"BMC Med Res Methodol"},{"key":"R11-20250613","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"key":"R12-20250613","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ahj.2006.01.007","article-title":"Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation","volume":"152","author":"Anand","year":"2006","journal-title":"Am Heart J"},{"key":"R13-20250613","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1177\/1074248415619490","article-title":"Effects of RAAS blockers on atrial fibrillation prophylaxis: an updated systematic review and meta-analysis of randomized controlled trials","volume":"21","author":"Chaugai","year":"2016","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"R14-20250613","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/j.1365-2362.2010.02460.x","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers decrease the incidence of atrial fibrillation: a meta-analysis","volume":"41","author":"Huang","year":"2011","journal-title":"Eur J Clin Invest"},{"key":"R15-20250613","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/0091270005283284","article-title":"The impact of suppressing the renin-angiotensin system on atrial fibrillation","volume":"46","author":"Kalus","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"R16-20250613","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ijcard.2012.02.009","article-title":"Blockade of the renin-angiotensin-aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: a systematic review and meta analysis of randomized controlled trials","volume":"165","author":"Khatib","year":"2013","journal-title":"Int J Cardiol"},{"key":"R17-20250613","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1111\/j.1540-8159.2004.00645.x","article-title":"The role of angiotensin receptor blockers and\/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: Meta-Analysis of Randomized Controlled Clinical Trials","volume":"27","author":"Madrid","year":"2004","journal-title":"Pacing Clin Electrophysiol"},{"key":"R18-20250613","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/clpt.2010.123","article-title":"The role of renin-angiotensin system blockade therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials","volume":"88","author":"Zhang","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"R19-20250613","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10557-011-6346-0","article-title":"Systematic review and meta-analysis: renin-Angiotensin system inhibitors in the prevention of atrial fibrillation recurrences: an unfulfilled hope","volume":"26","author":"Disertori","year":"2012","journal-title":"Cardiovasc Drugs Ther"},{"key":"R20-20250613","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/FJC.0b013e3182a094a1","article-title":"Renin-angiotensin system inhibitors prevent the recurrence of atrial fibrillation: a meta-analysis of randomized controlled trials","volume":"62","author":"Han","year":"2013","journal-title":"J Cardiovasc Pharmacol"},{"key":"R21-20250613","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.jacc.2004.11.070","article-title":"Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis","volume":"45","author":"Healey","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R22-20250613","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/ijcp.12063","article-title":"Renin-angiotensin system inhibitors for prevention of recurrent atrial fibrillation: a meta-analysis","volume":"67","author":"Li","year":"2013","journal-title":"Int J Clin Pract"},{"key":"R23-20250613","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/j.jacc.2010.01.043","article-title":"Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis","volume":"55","author":"Schneider","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R24-20250613","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/MJT.0b013e31804beb59","article-title":"Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system: a systematic review and meta-analysis","volume":"15","author":"Jibrini","year":"2008","journal-title":"Am J Ther"},{"key":"R25-20250613","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/1755-5922.12073","article-title":"Effect of telmisartan on atrial fibrillation recurrences in patients with hypertension: a systematic review and meta-analysis","volume":"32","author":"Pan","year":"2014","journal-title":"Cardiovasc Ther"},{"key":"R26-20250613","doi-asserted-by":"crossref","first-page":"e4059","DOI":"10.1097\/MD.0000000000004059","article-title":"Effect of RAAS blockers on adverse clinical outcomes in high CVD risk subjects with atrial fibrillation: a meta-analysis and systematic review of randomized controlled trials","volume":"95","author":"Chaugai","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"R27-20250613","doi-asserted-by":"crossref","first-page":"e194934","DOI":"10.1001\/jamanetworkopen.2019.4934","article-title":"Association of preoperative renin-angiotensin system inhibitors with prevention of postoperative atrial fibrillation and adverse events: a systematic review and meta-analysis","volume":"2","author":"Chen","year":"2019","journal-title":"JAMA Netw Open"},{"key":"R28-20250613","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.chest.2016.08.1476","article-title":"Prophylaxis against atrial fibrillation after general thoracic surgery: trial sequential analysis and network meta-analysis","volume":"151","author":"Zhao","year":"2017","journal-title":"Chest"},{"key":"R29-20250613","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/1074248410389045","article-title":"Prevention of recurrent atrial fibrillation with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers: a systematic review and meta-analysis of randomized trials","volume":"16","author":"Bhuriya","year":"2011","journal-title":"J Cardiovasc Pharmacol Ther"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025559","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T15:03:07Z","timestamp":1749826987000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025559"}},"subtitle":["An overview of systematic reviews"],"short-title":[],"issued":{"date-parts":[[2021,5,7]]},"references-count":29,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000025559","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2021,5,7]]},"assertion":[{"value":"2020-12-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}